Compare Godaddy Inc (GDDY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Godaddy Inc trades at $90.35 (market cap $11.49B), while Vertex Pharmaceuticals Incorporated trades at $530.1 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.7× Godaddy Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| GDDY | VRTX | |
|---|---|---|
Market Cap | $11.49B | $134.25B |
Sector | Technology | Health |
52-Week High | $148.88 | $529.65 |
52-Week Low | $75.07 | $376.62 |
Enterprise Value | $14.18B | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $91.49, up 0.46% today, with a neutral technical signal and strong fundamentals including a 17.83% net income margin and consistent earnings beats. Revenue growth is steady, projected at $5.1B for 2026, while recent news highlights legal investigations into potential securities violations, creating investor uncertainty.
The stock offers value with a P/E of 13.48 and a consensus price target of $112.13, but risks include ongoing legal scrutiny and high debt levels. Analyst sentiment remains bullish with 57% buy ratings, though technical indicators suggest near-term consolidation around key support at $90.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
